An Integrative Study on the Inhibition of Bone Loss via Osteo-F Based on Network Pharmacology, Experimental Verification, and Clinical Trials in Postmenopausal Women
The inhibition of bone loss remains a challenge for postmenopausal women, considering the fact that only three anabolic treatments for osteoporosis have been approved by the FDA. This study aimed to investigate the osteogenic capacities of Osteo-F, a newly developed herbal formula, upon integrating...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/12/15/1992 |
| _version_ | 1797586926485635072 |
|---|---|
| author | Mi Hye Kim Minkyung Bok Hyunjung Lim Woong Mo Yang |
| author_facet | Mi Hye Kim Minkyung Bok Hyunjung Lim Woong Mo Yang |
| author_sort | Mi Hye Kim |
| collection | DOAJ |
| description | The inhibition of bone loss remains a challenge for postmenopausal women, considering the fact that only three anabolic treatments for osteoporosis have been approved by the FDA. This study aimed to investigate the osteogenic capacities of Osteo-F, a newly developed herbal formula, upon integrating network analysis and pre-clinical studies into clinical trials. The network pharmacology analysis showed that a potential mechanism of Osteo-F is closely related to osteoblast differentiation. Consistent with the predicted mechanism, Osteo-F treatment significantly enhanced bone matrix formation and mineralization with collagen expression in osteoblasts. Simultaneously, secreted bone-forming molecules were upregulated by Osteo-F. After the administration of Osteo-F to osteoporotic mice, the femoral BMD and osteocalcin in the serum and bone tissues were significantly improved. Subsequently, a randomized, double-blinded, placebo-controlled clinical trial showed that 253 mg of Osteo-F supplementation for 24 weeks resulted in significant improvements in the Z-score and serum osteocalcin levels of postmenopausal women compared to the placebo, thus indicating bone anabolic efficacy. In the current study, the bone anabolic effect of Osteo-F was determined by activating the differentiation and mineralization of osteoblasts through integrating experiments based on network analysis into clinical trials, with synchronized, reliable evidence, demonstrating that Osteo-F is a novel bone anabolic treatment in postmenopausal women. |
| first_indexed | 2024-03-11T00:29:04Z |
| format | Article |
| id | doaj.art-19c2ee2a7e784a1db7df87dd2ce11637 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-11T00:29:04Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-19c2ee2a7e784a1db7df87dd2ce116372023-11-18T22:45:23ZengMDPI AGCells2073-44092023-08-011215199210.3390/cells12151992An Integrative Study on the Inhibition of Bone Loss via Osteo-F Based on Network Pharmacology, Experimental Verification, and Clinical Trials in Postmenopausal WomenMi Hye Kim0Minkyung Bok1Hyunjung Lim2Woong Mo Yang3Department of Convergence Korean Medical Science, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of KoreaDepartment of Medical Nutrition, Graduate School of East–West Medical Science, Kyung Hee University, Yongin 17104, Republic of KoreaDepartment of Medical Nutrition, Graduate School of East–West Medical Science, Kyung Hee University, Yongin 17104, Republic of KoreaDepartment of Convergence Korean Medical Science, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of KoreaThe inhibition of bone loss remains a challenge for postmenopausal women, considering the fact that only three anabolic treatments for osteoporosis have been approved by the FDA. This study aimed to investigate the osteogenic capacities of Osteo-F, a newly developed herbal formula, upon integrating network analysis and pre-clinical studies into clinical trials. The network pharmacology analysis showed that a potential mechanism of Osteo-F is closely related to osteoblast differentiation. Consistent with the predicted mechanism, Osteo-F treatment significantly enhanced bone matrix formation and mineralization with collagen expression in osteoblasts. Simultaneously, secreted bone-forming molecules were upregulated by Osteo-F. After the administration of Osteo-F to osteoporotic mice, the femoral BMD and osteocalcin in the serum and bone tissues were significantly improved. Subsequently, a randomized, double-blinded, placebo-controlled clinical trial showed that 253 mg of Osteo-F supplementation for 24 weeks resulted in significant improvements in the Z-score and serum osteocalcin levels of postmenopausal women compared to the placebo, thus indicating bone anabolic efficacy. In the current study, the bone anabolic effect of Osteo-F was determined by activating the differentiation and mineralization of osteoblasts through integrating experiments based on network analysis into clinical trials, with synchronized, reliable evidence, demonstrating that Osteo-F is a novel bone anabolic treatment in postmenopausal women.https://www.mdpi.com/2073-4409/12/15/1992bone anabolic effectclinical trialsnetwork analysisOsteo-Fosteoporosis |
| spellingShingle | Mi Hye Kim Minkyung Bok Hyunjung Lim Woong Mo Yang An Integrative Study on the Inhibition of Bone Loss via Osteo-F Based on Network Pharmacology, Experimental Verification, and Clinical Trials in Postmenopausal Women Cells bone anabolic effect clinical trials network analysis Osteo-F osteoporosis |
| title | An Integrative Study on the Inhibition of Bone Loss via Osteo-F Based on Network Pharmacology, Experimental Verification, and Clinical Trials in Postmenopausal Women |
| title_full | An Integrative Study on the Inhibition of Bone Loss via Osteo-F Based on Network Pharmacology, Experimental Verification, and Clinical Trials in Postmenopausal Women |
| title_fullStr | An Integrative Study on the Inhibition of Bone Loss via Osteo-F Based on Network Pharmacology, Experimental Verification, and Clinical Trials in Postmenopausal Women |
| title_full_unstemmed | An Integrative Study on the Inhibition of Bone Loss via Osteo-F Based on Network Pharmacology, Experimental Verification, and Clinical Trials in Postmenopausal Women |
| title_short | An Integrative Study on the Inhibition of Bone Loss via Osteo-F Based on Network Pharmacology, Experimental Verification, and Clinical Trials in Postmenopausal Women |
| title_sort | integrative study on the inhibition of bone loss via osteo f based on network pharmacology experimental verification and clinical trials in postmenopausal women |
| topic | bone anabolic effect clinical trials network analysis Osteo-F osteoporosis |
| url | https://www.mdpi.com/2073-4409/12/15/1992 |
| work_keys_str_mv | AT mihyekim anintegrativestudyontheinhibitionofbonelossviaosteofbasedonnetworkpharmacologyexperimentalverificationandclinicaltrialsinpostmenopausalwomen AT minkyungbok anintegrativestudyontheinhibitionofbonelossviaosteofbasedonnetworkpharmacologyexperimentalverificationandclinicaltrialsinpostmenopausalwomen AT hyunjunglim anintegrativestudyontheinhibitionofbonelossviaosteofbasedonnetworkpharmacologyexperimentalverificationandclinicaltrialsinpostmenopausalwomen AT woongmoyang anintegrativestudyontheinhibitionofbonelossviaosteofbasedonnetworkpharmacologyexperimentalverificationandclinicaltrialsinpostmenopausalwomen AT mihyekim integrativestudyontheinhibitionofbonelossviaosteofbasedonnetworkpharmacologyexperimentalverificationandclinicaltrialsinpostmenopausalwomen AT minkyungbok integrativestudyontheinhibitionofbonelossviaosteofbasedonnetworkpharmacologyexperimentalverificationandclinicaltrialsinpostmenopausalwomen AT hyunjunglim integrativestudyontheinhibitionofbonelossviaosteofbasedonnetworkpharmacologyexperimentalverificationandclinicaltrialsinpostmenopausalwomen AT woongmoyang integrativestudyontheinhibitionofbonelossviaosteofbasedonnetworkpharmacologyexperimentalverificationandclinicaltrialsinpostmenopausalwomen |